WASHINGTON – Investors were relieved Monday after FDA reviewers said Valeant Pharmaceuticals International Inc.'s experimental epilepsy drug Potiga (ezogabine/retigabine) was effective as an adjunctive treatment for partial onset seizures. (BioWorld Today)

Seeking to boost its balance sheet, Arena Pharmaceuticals Inc. Friday revealed a new direct public offering of 8.95 million shares at $6.70 per share, with expected proceeds of $60 million – $30 million of which the firm plans to use to prepay a portion of a loan. (BioWorld Today)